Taken together, the aforementioned results imply that the observed anti-tumor responses imposed by CSF1R inhibition induced a compensatory upregulation of PD-1/PDL1 immune escape signals, which may partially limit the anti-tumor effect of the inhibitor. Here, CSF1R is linked to neoplasm.